Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.41 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125355 | 0.90 | MET (0.53) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL13455063 | 0.87 | MET (0.51) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL5254616 | 0.79 | MET (0.65) | METALKJAK2 | |
| SCHEMBL3110705 | 0.78 | MET (0.58) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL5930748 | 0.76 | MET (0.64) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL30452512 | 0.75 | MET (0.78) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL487718 | 0.75 | MET (0.78) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL12993476 | 0.75 | MET (0.58) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL30452650 | 0.74 | MET (0.64) | METALKMAP4K2MAP3K1AAK1 | |
| SCHEMBL488074 | 0.74 | MET (0.64) | METALKMAP4K2MAP3K1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324061-A1 | including crizotinib which is 3-[(R)-1-(2-chloro-3,6-difluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; c-met inhibitors; hepatocyte growth factor (HGF) receptor (c-MET) receptor tyrosine kinase (RTK) | AGOURON PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324061-A1 | including crizotinib which is 3-[(R)-1-(2-chloro-3,6-difluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; c-met inhibitors; hepatocyte growth factor (HGF) receptor (c-MET) receptor tyrosine kinase (RTK) | MET, HGF, ALK | MET 1/4885ALK 3/4885MAP4K2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.